Syglak Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-12-2024
- Paid Up Capital ₹ 0.27 M
as on 04-12-2024
- Company Age 20 Year, 19 Days
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 4.36 Cr
as on 04-12-2024
- Revenue -74.53%
(FY 2017)
- Profit -61.64%
(FY 2017)
- Ebitda -18.32%
(FY 2017)
- Net Worth 1.08%
(FY 2017)
- Total Assets 7.02%
(FY 2017)
About Syglak Laboratories
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.27 M.
The company currently has active open charges totaling ₹4.36 Cr.
Lav Vadehra and Gaurav Vadehra serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PTC149815
- Company No.
149815
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2004
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Syglak Laboratories Private Limited offer?
Syglak Laboratories Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anesthetic.
Who are the key members and board of directors at Syglak Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Vadehra  | Director | 21-Jul-2015 | Current |
| Lav Vadehra | Director | 14-Feb-2014 | Current |
Financial Performance of Syglak Laboratories.
Syglak Laboratories Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 74.53% decrease. The company also saw a substantial fall in profitability, with a 61.64% decrease in profit. The company's net worth moved up by a moderate rise of 1.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syglak Laboratories?
In 2018, Syglak Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Glazers Exports (India) Pvt LtdActive 44 years 5 months
Lav Vadehra and Gaurav Vadehra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Feb 2018 | ₹2.86 Cr | Open |
Syndicate Bank Creation Date: 11 Feb 2013 | ₹0.19 M | Open |
Syndicate Bank Creation Date: 11 Feb 2013 | ₹0.80 M | Open |
How Many Employees Work at Syglak Laboratories?
Unlock and access historical data on people associated with Syglak Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syglak Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syglak Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
